Population pharmacokinetics of arbekacin, vancomycin, and panipenem in Neonates

被引:69
|
作者
Kimura, T
Sunakawa, K
Matsuura, N
Kubo, H
Shimada, S
Yago, K
机构
[1] Kitasato Univ Hosp, Dept Pharm, Kanagawa 2288555, Japan
[2] Kitasato Univ Hosp, Div Neonatol, Kanagawa 2288555, Japan
[3] Kitasato Univ, Div Infect Dis, Sch Med, Kanagawa 2288555, Japan
[4] Kitasato Univ, Sch Pharmaceut Sci, Analyt Chem Lab, Minato Ku, Tokyo 1088641, Japan
关键词
D O I
10.1128/AAC.48.4.1159-1167.2004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Immature renal function in neonates requires antibiotic dosage adjustment. Population pharmacokinetic studies were performed to determine the optimal dosage regimens for three types of antibiotics: an aminoglycoside, arbekacin; a glycopeptide, vancomycin; and a carbapenem, panipenem. Eighty-three neonates received arbekacin (n=41), vancomycin (n=19), or panipenem (n=23). The postconceptional ages (PCAs) were 24.1 to 48.4 weeks, and the body weights (BWs) ranged from 458 to 5,200 g. A one-compartment open model with first-order elimination was applied and evaluated with a nonlinear mixed-effect model for population pharmacokinetic analysis. In the fitting process, the fixed effects significantly related to clearance (CL) were PCA, postnatal age, gestational age, BW, and serum creatinine level; and the fixed effect significantly related to the volume of distribution (V) was BW. The final formulas for the population pharmacokinetic parameters are as follows: CLarbekacin=0.0238 x BW/serum creatinine level for PCAs of <33 weeks and CLarbekacin=0.0367 x BW/serum creatinine level for PCAs of >= 33 weeks, V-arbekacin=0.54 liters/kg, CLvancomycin=0.0250 x BW/serum creatinine level for PCAs of <34 weeks and CLvancomycin=0.0323 x BW/serum creatinine level for PCAs of greater than or equal to34 weeks, V-vancomycin=0.66 liters/kg, CLpanipenem=0.0832 for PCAs of <33 weeks and CLpanipenem=0.179 x BW for PCAs of >= 33 weeks, and V-panipenem=0.53 liters/kg. When the CL of each drug was evaluated by the nonlinear mixed-effect model, we found that the mean CL for subjects with PCAs of <33 to 34 weeks was significantly smaller than those with PCAs of greater than or equal to33 to 34 weeks, and CL showed an exponential increase with PCA. Many antibiotics are excreted by glomerular filtration, and maturation of glomerular filtration is the most important factor for estimation of antibiotic clearance. Clinicians should consider PCA, serum creatinine level, BW, and chemical features when determining the initial antibiotic dosing regimen for neonates.
引用
收藏
页码:1159 / 1167
页数:9
相关论文
共 50 条
  • [21] Vancomycin pharmacokinetics in neonates extracorporeal membrane oxygenation
    Buck, ML
    PHARMACOTHERAPY, 1998, 18 (05): : 1082 - 1086
  • [22] VANCOMYCIN PHARMACOKINETICS IN NEONATES AND INFANTS - A RETROSPECTIVE EVALUATION
    ASBURY, WH
    DARSEY, EH
    ROSE, WB
    MURPHY, JE
    BUFFINGTON, DE
    CAPERS, CC
    ANNALS OF PHARMACOTHERAPY, 1993, 27 (04) : 490 - 496
  • [23] POPULATION PHARMACOKINETICS (PK) OF VANCOMYCIN (VAN) IN NEONATES ON EXTRA-CORPOREAL LIFE SUPPORT
    Cies, Jeffrey
    Moore, Wayne
    Nichols, Kristen
    Knoderer, Chad
    Carella, Dominick
    Parker, Jason
    Shea, Paul
    Chopra, Arun
    CRITICAL CARE MEDICINE, 2015, 43 (12)
  • [24] Population pharmacokinetics of vancomycin and AUC-guided dosing in Chinese neonates and young infants
    Yewei Chen
    Dan Wu
    Min Dong
    Yiqing Zhu
    Jinmiao Lu
    Xiaoxia Li
    Chao Chen
    Zhiping Li
    European Journal of Clinical Pharmacology, 2018, 74 : 921 - 930
  • [25] Population pharmacokinetics of vancomycin and AUC-guided dosing in Chinese neonates and young infants
    Chen, Yewei
    Wu, Dan
    Dong, Min
    Zhu, Yiqing
    Lu, Jinmiao
    Li, Xiaoxia
    Chen, Chao
    Li, Zhiping
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (07) : 921 - 930
  • [26] Improving Precision of Vancomycin Dosing in Neonates Based on Clinical Outcome Evaluation and Population Pharmacokinetics
    Chung, E.
    Pelle, B.
    Seto, W.
    CANADIAN JOURNAL OF HOSPITAL PHARMACY, 2023, 76 (02): : 152 - 152
  • [27] The usefulness of arbekacin compared to vancomycin
    Hwang, J. -H.
    Lee, J. -H.
    Moon, M. -K.
    Kim, J. -S.
    Won, K. -S.
    Lee, C. -S.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2012, 31 (07) : 1663 - 1666
  • [28] Population pharmacokinetic study of vancomycin in neonates
    Colom, H.
    Armendariz, Y.
    Pou, L.
    THERAPEUTIC DRUG MONITORING, 2007, 29 (04) : 534 - 534
  • [29] Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance
    Anderson, Brian J.
    Allegaert, Karel
    Van den Anker, John N.
    Cossey, Veerle
    Holford, Nicholas H. G.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 63 (01) : 75 - 84
  • [30] Pharmacokinetics and administration regimens of vancomycin in neonates, infants and children
    Rodvold, KA
    Everett, JA
    Pryka, RD
    Kraus, DM
    CLINICAL PHARMACOKINETICS, 1997, 33 (01) : 32 - 51